Skip to main content

Donegan Michael C's Form 4 filing

TherapeuticsMD, Inc. (TXMD) · filed Dec 9, 2022

Accession no.
0001209191-22-060585
Filed
Dec 9, 2022
Trade date
Dec 6, 2022
Filing delay
3 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $4.35K. It was filed 3 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Donegan Michael CCIK 0001627810Officer (Interim CFO/CAO/VP of Finance)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 6, 2022Common StockMOption exerciseAcquired+2,300$0.00$04,288Direct
Dec 6, 2022Common StockMOption exerciseAcquired+380$0.00$04,668Direct
Dec 6, 2022Common StockMOption exerciseAcquired+534$0.00$05,202Direct
Dec 6, 2022Common StockMOption exerciseAcquired+262$0.00$05,464Direct
Dec 6, 2022Common StockSSaleDisposed−910$4.78−$4,349.84,554Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 6, 2022Common StockMOption exerciseDisposed−2,300$0.00$00Direct
Dec 6, 2022Common StockMOption exerciseDisposed−380$0.00$0380Direct
Dec 6, 2022Common StockMOption exerciseDisposed−534$0.00$01,066Direct
Dec 6, 2022Common StockMOption exerciseDisposed−262$0.00$0519Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)